CLS-015 (DFF) is positioned to enhance the efficacy of anti-CD19 CAR-T therapies in patients with large B-cell lymphoma, particularly those with stable or progressive disease during lymphodepletion. The study addresses a significant unmet medical need, as current CAR-T therapies have limited effectiveness in this patient population, with high rates of disease progression. If successful, CLS-015 could capture a niche market within the CAR-T therapy landscape, potentially leading to partnerships with CAR-T developers or positioning as a complementary therapy. The competitive landscape includes existing CAR-T therapies and emerging agents targeting similar patient populations, necessitating a robust clinical profile to differentiate CLS-015. Diligence should focus on the safety profile and the ability to demonstrate improved clinical outcomes over existing therapies.